Develops therapeutic products to treat neurodegenerative diseases, focusing on Parkinsonian and related disorders.
Alterity Therapeutics Limited, headquartered in Melbourne, Australia, is dedicated to advancing therapeutic drugs aimed at combating Alzheimer's disease, Huntington's disease, Parkinson's disease, and various other neurological disorders. Central to its portfolio is ATH434, the company's lead drug candidate which has successfully completed Phase I clinical trials for Parkinson's disease. Additionally, Alterity Therapeutics is actively developing PBT2, a promising compound that has completed Phase 2a clinical trials targeting Alzheimer's disease, demonstrating its commitment to addressing significant unmet medical needs in neurology.
Originally established as Prana Biotechnology Limited in 1997, Alterity Therapeutics underwent a transformative name change in April 2019 to better align its corporate identity with its evolving focus and strategic direction. With over two decades of experience in neuroscience research and development, the company leverages its deep scientific expertise to pioneer innovative treatments that offer hope to patients worldwide suffering from debilitating neurological conditions.
Alterity Therapeutics operates at the forefront of neurology research, employing a rigorous approach to drug discovery and development. Supported by a team of dedicated scientists and professionals, the company is committed to advancing its pipeline of novel therapies with the potential to transform the treatment landscape for neurological disorders. By harnessing cutting-edge research and strategic partnerships, Alterity Therapeutics remains steadfast in its mission to deliver meaningful therapeutic advancements that improve the lives of patients and caregivers affected by these challenging diseases.